Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

NCT00217581 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Docetaxel
DRUG: Oxaliplatin

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]